Pfizer Announces Updated Real-World Data Confirming Paxlovid Effectiveness Against New COVID Variants

Pfizer today announced updated real-world data from multiple healthcare systems showing that Paxlovid (nirmatrelvir/ritonavir) maintains effectiveness against newer SARS-CoV-2 variants in high-risk patients. The analysis included data from over 50,000 patients treated with Paxlovid during periods when newer variants were predominant. The data showed a 55% reduction in hospitalization risk compared to untreated high-risk patients. These results provide reassurance that Paxlovid continues to provide meaningful clinical benefit against evolving SARS-CoV-2 variants. Pfizer continues to monitor Paxlovid effectiveness against emerging variants.